Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2011-01-11
2011-01-11
Skelding, Zachary (Department: 1644)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S144100, C424S183100
Reexamination Certificate
active
07867475
ABSTRACT:
Disclosed are methods of treating subjects having disorders or conditions characterized by an unwanted immune response including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.
REFERENCES:
patent: 2002/0039557 (2002-04-01), White
patent: 2002/0114781 (2002-08-01), Strom et al.
patent: 2003/0118592 (2003-06-01), Ledbetter et al.
patent: 1004667 (2000-05-01), None
patent: 2192128 (2003-09-01), None
patent: 9521618 (1995-08-01), None
patent: 01/05964 (2001-01-01), None
patent: 2004069183 (2004-08-01), None
McInnes et al., Immunol Today. Feb. 1998;19(2):75-9.
McInnes et al., Nat Med. Feb. 1997;3(2):189-95.
Colman et al., Research in Immunology, 1994; 145(1): 33-36.
Abaza et al., Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444.
Lederman et al., Molecular Immunology 28: 1171-1181, 1991.
Cheon et al., Clin. Exp. Immunol. Mar. 2002;127(3):547-52.
Xiao-Hong et al., Proc Natl Acad Sci U S A. May 11, 1999;96(10):5692-7.
Marzio et al., Immunopharmacol Immunotoxicol. Aug. 1999;21(3):565-82.
Craston et al., J Immunol Methods. Nov. 10, 1997;209(1):37-45.
Van der Lubbe et al., J Autoimmun. Feb. 1997;10(1):87-97.
Choy et al., British Journal of Rheumatology 1998;37:484-490.
Black et al., Arthritis Res. 2002;4(3):177-83.
Chace et al., J. Immunol. 1994;152;405-412.
Ziegler et al., Stem Cells. Sep. 1994;12(5):456-65.
Blood Work: a complete Guide for Monitoring HIV, project inform, May 2007, pp. 1-12.
Ziegler, S.F. et al. (1993) Molecular characterization of the early activation antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation antigens. Eur. J. Immunol. 23, 1643-1648.
Lopez-Cabrera, M. et al. (1993) Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J. Exp. Med. 178, 537-547.
Testi, R. et al. (1994) The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol. Today 15, 479-483.
Long, E.O. (1999) Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17, 875-904.
Pisegna, S. et al. (2002) Src-dependent Syk activation controls CD69- mediated signaling and function on human NK cells. J. Immunol. 169, 68-74.
Zingoni, A. et al. (2000) CD69-triggered ERK activation and functions are negatively regulated by CD94/NKG2-A inhibitory receptor. Eur. J. Immunol. 30, 644-651.
Risso, A. et al. (1991) CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression. J. Immunol. 146, 4105-4114.
Bikah, G. et al. (2000) Regulating T helper cell immunity through antigen responsiveness and calcium entry. Nat. Immunol. 1, 402-412.
Sancho, D. et al. (2000) Functional analysis of ligand-binding and signal transduction domains of CD69 and CD23 C-type lectin leukocyte receptors. J. Immunol. 165, 3868-3875.
Testi, R. et al. (1989) T cell activation via Leu-23 (CD69). J. Immunol. 143,1123-1128.
Cebrián, M. et al. (1988) Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J. Exp. Med. 168,1621-1637.
Santis, A.G. et al. (1992) Tumor necrosis factor-a production induced in T lymphocytes through the AIM/CD69 activation pathway. Eur. J. Immunol. 22,1253-1259.
De-Maria, R. et al. (1994) Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors. J. Exp. Med. 180, 1999-2004.
Testi, R. et al. (1990) CD69 is expressed on platelets and mediates platelet activation and aggregation. J. Exp. Med. 172,701-707.
Ramirez, R. et al. (1996) CD69-induced monocyte apoptosis involves multiple nonredundant signaling pathways. Cell. Immunol. 172,192-199.
Walsh, G.M. et al. (1996) Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating factor. Blood 87,2815-2821.
Cosulich, M.E. et al. (1987) Functional characterization of an antigen involved in an early step of T-cell activation. Proc. Natl. Acad. Sci. U. S. A. 84,4205-4209.
Feng, C. et al. (2002) A potential role for CD69 in thymocyte emigration. Int. Immunol. 14,535-544.
Nakayama, T. et al. (2002) The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression. J. Immunol. 168, 87-94.
Lauzurica, P. et al. (2000) Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice. Blood 95,2312-2320.
Laffón, A. et al. (1991) Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. 88, 546-552.
Remmers, E.F. et al. (1996) A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. Nat. Genet. 14,82-85.
Mc Indoe, R.A. et al. (1999) Localization of non-MHC collagen-induced arthritis susceptibility loci inDBA/lj mice. Proc.Natl.Acad. Sci. U. S. A. 96,2210-2214.
Brandes, M.E. et al. (1991) Transforming growth factor b1 suppresses acute and chronic arthritis in experimental animals. J. Clin. Invest. 87,1108-1113.
Grewal, J.S. et al. (1999) Serotonin 5-HT2A receptor induces TGF-bl expression in mesangial cells via ERK: proliferative and fibrotic signals. Am. J. Physiol. Renal Physiol. 276, F922-F930.
Gorelik, L. and Flavell, R.A. (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-b signaling in T cells. Nat. Med. 7,1118-1122.
Gorelik, L. et al. (2002) Mechanism of transforming growth factor b-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 195,1499-1505.
Cazac, B.B. And Roes, J. (2000) TGF-b receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13,443-451.
Fava, R.A. et al. (1991) Transforming growth factor 1 induced neutrophil recruitment to synovial tissues: implications for TGF-b driven synovial inflammation and hyperplasia. J. Exp. Med. 173,1121-1132.
Sancho, D. et al. (1999) Activation of peripheral blood T cells by interaction and migration through endothelium: role of lymphocyte function antigen-1/intercellular adhesion molecule-1 and interleukin-15. Blood 93, 886-896.
Fava, R. et al. (1989) Active and latent forms of transforming growth factor b activity in synovial effusions. J. Exp. Med. 169,291-296.
Yu, X. et al. (2001) Anti-CD69 autoantibodies cross-react with low density lipoprotein receptor-related protein 2 in systemic autoimmune diseases. J. Immunol. 166,1360-1369.
Kulkarni, A.B. et al. (1993) Transforming growth factor bl null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. U. S. A. 90,770-774.
Shull, M.M. et al. (1992) Targeted disruption of the mouse transforming growth factor-b1 gene results in multifocal inflammatory disease. Nature 359, 693-699.
Shevach, E.M. (2002) CD4+CD25+suppressor T-cells: more questions than answers. Nat. Rev. Immunol. 2, 389-400.
Chatenoud, L et al. (1997) Induced dominant self-tolerance in overtly diabetic Nod mice. J. Immunol. 158, 2947-2954.
Ishikawa, S. et al. (1998) A subset of CD4C T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance. J. Immunol. 161,1267-1273.
Portales-Perez, D. et al. (1997) Abnormalities in CD69 expression, cytosolic pH and Ca2C during activation of lymphocytes from patients with systemic lupus erythematosus. Lupus 6,48-56.
Hernandez-Garda, C. et al. (1996) The CD69 activation pathway in rheumatoid arthritis synovial fluid T cells. Arthritis Rheum. 39,1277-1286.
McGuirk, P. and Mills, L. (2002) Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol. 23,450-455.
Swat, W. et al. (1993) CD69 expression during selection and maturatio
Alonso Carlos Martinez
Artola Enric Esplugues
Gómez Pilar Lauzurica
Madrid David Sancho
Ramos Javier Vega
Consejo Superior de Investigaciones Cientificas
Elrifi Ivor R.
Gomóez Pilar Lauzurica
Kozakiewicz Cynthia A.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Immune regulation based on the depletion of CD69+ cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immune regulation based on the depletion of CD69+ cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune regulation based on the depletion of CD69+ cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722293